Docebo (DCBO) EBITDA (2019 - 2026)

Docebo (DCBO) has reported EBITDA for 8 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 37.66% year-over-year to $2.6 million; the trailing twelve-month figure through Jun 2026 stood at $18.5 million (changed 0.47% YoY), and the FY2025 full-year result was $23.2 million, up 9.13% from the prior year.
• EBITDA advanced to $2.6 million in Q2 2026 per DCBO's latest filing, from -$1.5 million in the prior quarter.
• Across five years, EBITDA topped out at $9.3 million in Q4 2025 and bottomed at -$7.5 million in Q2 2023.
• Historically, EBITDA has averaged $3.0 million across 5 years, with a median of $3.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA plunged 457.0% in 2023, then jumped 1224.2% in 2024.
• Over 5 years, EBITDA stood at $2.3 million in 2022, then jumped by 187.61% to $6.5 million in 2023, then climbed by 20.38% to $7.8 million in 2024, then grew by 19.36% to $9.3 million in 2025, then sank by 72.37% to $2.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $2.6 million, -$1.5 million, and $9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.